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Abstract 
Obesity through its association with type 2 diabetes (T2D), cancer and cardiovascular diseases (CVDs), poses a serious 
health threat, as these diseases contribute to high mortality rates. Pharmacotherapy alone or in combination with 
either lifestyle modification or surgery, is reliable in maintaining a healthy body weight, and preventing progression 
to obesity-induced diseases. However, the anti-obesity drugs are limited by non-specificity and unsustainable weight 
loss effects. As such, novel and improved approaches for treatment of obesity are urgently needed. Nanotechnol-
ogy-based therapies are investigated as an alternative strategy that can treat obesity and be able to overcome the 
drawbacks associated with conventional therapies. The review presents three nanotechnology-based anti-obesity 
strategies that target the white adipose tissues (WATs) and its vasculature for the reversal of obesity. These include 
inhibition of angiogenesis in the WATs, transformation of WATs to brown adipose tissues (BATs), and photothermal 
lipolysis of WATs. Compared to conventional therapy, the targeted-nanosystems have high tolerability, reduced side 
effects, and enhanced efficacy. These effects are reproducible using various nanocarriers (liposomes, polymeric and 
gold nanoparticles), thus providing a proof of concept that targeted nanotherapy can be a feasible strategy that can 
combat obesity and prevent its comorbidities.
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Introduction
Obesity is a global epidemic that results from increased 
energy intake and storage of excess fat within the WAT 
depots [1–3]. Prolonged energy imbalance due to excess 
energy intake and less energy expenditure has been 
associated with development of life threatening diseases 
such as CVDs, some form of cancers and metabolic dis-
eases [4, 5]. As a chronic disease, anti-obesity treatments 
relies on lifestyle modification, surgery, and pharmaco-
therapy. Pharmacotherapy in combination with lifestyle 
modification and surgery, is used to maintain a healthy 
body weight [5]. However, the success of anti-obesity 
drugs in reducing body weight is often counteracted by 
side effects, which have led to withdrawal of several anti-
obesity drugs from the market [1, 2, 5]. There is clearly 
a need for new and improved anti-obesity strategies with 
sustainable weight loss effects and minimal bystander 
effects towards healthy tissues. Dysfunction in the WATs 
is the root cause of obesity and obesity-related diseases, 
hence this tissue is an ideal target for therapeutic inter-
vention. The WATs express more than fifty adipokines, 
some of which are implicated in the development of obe-
sity and its associated metabolic diseases [6–8]. Leptin 
[7, 9] and adiponectin [7, 10], expressed primarily by the 
adipocytes, are on top of the list. Prohibitin (PHB) [11] 
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in pre-clinical studies, and have shown potential for clini-
cal application. Therefore, the WATs can be exploited 
through various molecules secreted or expressed by the 
cells that make up this tissue (adipocytes, lymphocytes, 
macrophages, fibroblasts, and vascular cells) for treat-
ment of obesity.
Targeting the disease-associated biomarkers might 
provide insights on the pathophysiology, prevention and 
management of obesity and its related diseases [8], and 
could potentially be used for improving the efficacy of 
existing drugs or those that had been withdrawn from the 
market. Great efforts have been made through targeted 
nanotechnology-based treatments, where nanocarriers 
were used as drug delivery vehicles to improve the phar-
macokinetics of anti-obesity agents. This review focuses 
on three potential nanotechnology-based anti-obesity 
strategies targeted on the WAT and its vascular system. 
These treatment strategies are based on the following 
three mechanisms (1) inhibition of angiogenesis in the 
WAT vasculature [13–15], (2) transformation of WAT 
into BAT [12, 16, 17], as well as (3) photothermal lipolysis 
of WAT [18, 19]. The targeted nano-based systems were 
able to deliver the therapeutic agents specifically at the 
local tissues, reduce drug toxicity towards healthy tis-
sues, and was more effective at very low dosages [13–19]. 
The preclinical studies presented in this review article 
provide evidence that targeted nanotherapy could serve 
as an alternative treatment for obesity and prevent its 
progression to obesity-induced diseases.
Obesity and challenges of current drug treatments
Obesity is a global health concern and a chronic disease 
that affects millions of people worldwide, both children 
and adults alike [5, 20]. The epidemic has been grow-
ing steadily long before it was considered to be a disease 
by the American Medical Association in 2013 [21]. The 
global statistics for adult males and females (≥ 18 years) 
indicate that since 1975 women are more prone to obe-
sity than men. Of concern is that these rates have more 
than tripled for men, from 3.2% in 1975, which was half 
of what was recorded for women (6.4%) to 11% in 2016 
which is 4% less than the rate for women. The cur-
rent global statistics indicate that 13% (650 million) 
of the adult population are obese, while 1.9 billion are 
overweight [20]. These numbers are alarming, and are 
expected to escalate if not addressed. It is estimated that 
60% of global deaths in the next 6  years (2025) will be 
caused by obesity-related diseases [5, 20]. These projec-
tions highlight the need for the obesity epidemic to be 
addressed with more urgency [20].
Obesity occurs due to energy imbalance between 
energy intake and energy expenditure in the WATs 
for a prolonged period. In genetically susceptible 
individuals, it can be triggered by environmental factors 
such as high caloric diets and lack of physical activity. 
Body mass index (BMI), i.e. BMI = weight (kg)/height2 
(m) is the most widely used method for measurement 
of obesity. Generally, individuals with a BMI range of 
18.5–24.9  kg/m2 are considered to be normal (healthy), 
while those with a BMI that is < 18.5 and ≥ 25 kg/m2 are 
said to have unhealthy body weights. According to the 
BMI weight status, adults (≥ 18  years) are categorized 
as overweight at a BMI ≥ 25–29.9  kg/m2, and anyone 
with a BMI ≥ 30 kg/m2 are classified as obese [1–3, 22]. 
If left untreated for a longer period, obesity can predis-
pose patients to various chronic diseases, which include 
metabolic, CVDs, inflammatory and malignant diseases 
[4, 5]. These diseases reduce life expectancy and contrib-
ute to high mortality rates, of which cancer and CVDs are 
among the leading causes of death worldwide. Obesity is 
a chronic disease and currently there is no single treat-
ment strategy that can completely cure it. Clinically it can 
be managed through lifestyle modification, pharmaco-
therapy, and surgery in severe cases [1, 2, 5].
Obesity management primarily relies on pharmaceuti-
cal drugs to maintain a healthy body weight and prevent 
its progression to related chronic diseases [1, 23, 24]. 
These pharmaceutical drugs are only recommended for 
overweight and obese patients who are non-responsive 
to lifestyle modification within the first 6  months, and 
suffer from at least one of the obesity-induced diseases 
[1–3]. There are various anti-obesity drugs available for 
short-term and long-term use, these drugs work mainly 
in the central nervous system, gut and intestines to either 
suppress appetite, inhibit fat absorption, or increase 
energy expenditure [1, 2, 25]. Short-term drugs include: 
phentermine [26–28], diethylpropion, mazindol, ben-
zphetamine, and phendimetrazine [25, 29]. Orlistat and 
liraglutide have been approved for long-term treatment 
of obesity [25, 30]. Orlistat reduces body weight by block-
ing fat absorption in the gut through inhibition of gastric 
and pancreatic lipases. However, the effectiveness of this 
drug have been overshadowed by side effects; limiting its 
use to a period not longer than 2 years [31, 32]. The side 
effects include oily spotting, flatus with discharge, fecal 
urgency, fatty/oily stool, oily evacuation, increased def-
ecation, and fecal incontinence [26–28] Liraglutide is a 
human glucagon-like peptide-1 (GLP-1) receptor agonist. 
GLP-1 is an incretin hormone secreted by the L-cells of 
the gastrointestinal tract, the hormone stimulate insulin 
secretion, reduce blood glucagon levels; its anti-obesity 
activity are attributed to its ability to delay gastric emp-
tying and appetite suppression effects. In addition to the 
drug ‘s gastrointestinal side effects, it increases the risk of 
pancreatitis and increases the heart rate [26–28, 33]. Fur-
thermore, the drug is available as an injectable and not 
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as a convenient oral dosage form, thus reducing patient’s 
compliance [33].
The usefulness of the anti-obesity drugs is mostly lim-
ited by non-specificity, poor efficacy, and bystander 
effects. In cases where the side effects surpassed the 
efficacy of the drugs, this led to the withdrawal of most 
potent drugs [23]. Some of the drugs that have been 
removed from the market include amphetamine ana-
logs, sympathomimetics and cannabinoid agonists. 
The anti-obesity effects of these drugs (e.g. aminorex, 
ephedrine, fenfluramine-phentermine, rimonabant, and 
sibutramine) were tainted by their undesirable toxic side 
effects which included cardiac valve defects, pulmonary 
hypertension, stroke, psychotic behaviors, addiction lia-
bility, and in some cases death [1, 2, 24, 25].
For the recent FDA-approved anti-obesity drugs, fail-
ure to lose at least 5% of the body weight within 12 weeks 
calls for drug discontinuation [34]. To date there is no 
pharmacologic therapy that has succeeded in maintain-
ing a weight loss of over 10% for 1 year. For some, bari-
atric surgery (e.g. gastric bypass) is an option, however, 
weight regain is a common occurrence following surgery. 
Thus, there is an urgent need to find or develop alterna-
tive treatment strategies with minimal side effects and 
sustainable weight loss effects. This can be achieved by 
targeting the tissues that are directly involved in obesity 
development, mainly the WATs, targeted therapy might 
be more effective in treating obesity as a disease. Treat-
ing the underlying disease will in turn reduce the obesity-
induced chronic diseases.
AT as an ideal target for obesity treatment
Formerly thought to be an inert fat storage organ, the 
adipose tissue (AT) has been recognized as an endocrine 
organ that plays a crucial role in the body’s homeostasis 
[35–37]. It accounts for less than 30 and up to 80% of total 
body weight mass in lean and obese humans, respec-
tively. There are two main types of ATs, that differ in their 
function and anatomical location, namely, the brown adi-
pose tissue (BAT) and the white adipose tissue (WAT) 
[35, 36, 38]. The BAT is located mainly in the intrascap-
ular or supraclavicular region [23, 39, 40]. Intrascapular 
BAT is abundant in rodents and hibernating animals. 
In humans, BAT is more prominent in newborn babies 
and adults with high metabolic rates [23, 39–41]. Human 
BAT function is high in newborns, and diminishes with 
age and increased body weight. The energy expenditure 
in BAT is promoted by high levels of uncoupling protein 
(UCP)-1 in brown adipocytes. BAT is an energy dissipat-
ing organ that is responsible for adaptive thermogenesis 
[38, 42–44]. It preserves homeostasis by uncoupling oxi-
dative metabolism from ATP production in order to pro-
duce heat via UCP-1 during cold exposure. The recent 
identification of BAT in adult humans has sparked inter-
est to explore it for obesity treatment [38, 45–48].
The WATs are found in various places all over the body. 
Their major depots include the subcutaneous (inguinal) 
which is located under the skin is the largest depot, and 
visceral (retroperitoneal, perirenal, epididymal, mes-
enteric, ovarian) depots, located around the kidney, 
intestines, pericardial, and ovaries. This tissue is mostly 
involved in storage of excess energy in the form of tria-
cylglycerides (TAGs), which can be converted to glucose 
during the fasting state [36]. It is recognized that visceral 
WAT, which account for much less in body mass, poses 
a far greater risk for obesity patients. Up until 1994, the 
WAT was perceived as a passive organ that simply store 
excess fat. And after the discovery of leptin, it was evi-
dent this tissue, through its secretory molecules (known 
as adipokines), is involved in the metabolic and physi-
ological functions of the body. Leptin, although secreted 
by the WAT, also regulates satiety signals in the brain [3, 
9]. More than 50 other adipokines are known to date, 
which are responsible for the autocrine, endocrine and 
paracrine functions of the WAT. Some of their meta-
bolic functions include glucose metabolism (adiponectin, 
resistin), lipid metabolism (adiponectin, TNF-α, interleu-
kin-6), insulin sensitivity (adiponectin, visfatin), vascular 
remodeling (chemerin) and many more [36].
The WAT is central in the development of obesity and 
its associated diseases. As a consequence of chronic 
intake of excess energy, the WAT expands by increas-
ing the number of pre-adipocytes (hyperplasia) and the 
size of adipocytes (hypertrophy) [36]. Obesity alters the 
WAT functions and homeostasis, whereby the changes in 
adipokine expression affects the activity of other major 
organs such as brain, liver, kidney, heart and muscles 
(Fig. 1). Alteration of the physiological activities in these 
organs is accompanied by development of secondary dis-
eases [4, 5], for instance chronic ectopic fat in the liver 
could lead to development of hepatic steatosis [49]. These 
adipokines are used clinically to assess the presence or 
absence of obesity-induced diseases, as well as targets 
for therapeutic intervention [50, 51]. Some of them have 
been explored in preclinical studies as targets for drug 
therapy and to assess progression to other diseases [11, 
13, 14, 16]. Therefore, strategies that are targeted at the 
WAT to reduce its size, destroy the hypertrophic adipo-
cytes, transform WAT to BAT or inhibit adipogenesis 
could be ideal not only for obesity treatment but its asso-
ciated comorbidities as well.
Targeted nanotherapy for treatment of obesity
Pharmacotherapy still remains an area of ongoing 
research in search for a magic anti-obesity drug that will 
have significant and sustainable weight loss effects. Since 
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the introduction of thyroid hormone as the first anti-obe-
sity drug in 1893, most of the drugs that followed have 
been withdrawn due to their adverse side effects in obese 
patients [1, 2, 5, 29, 52]. Thus, extreme caution is man-
datory before considering any drugs for the treatment of 
obesity. In addition to the drug’s efficacy, its safety profile 
is equally as important. In recent years, experimental tar-
geted therapy has been reported to promote substantial 
weight loss with reduced side effects in animal models of 
obesity [11, 53]. These anti-obesity effects were enhanced 
by using nanotechnology-based delivery systems [13–19]. 
Three nano-based strategies that focused on the WAT 
and its vasculature as a target for obesity therapeutic 
intervention are reviewed here.
Inhibition of angiogenesis in WAT reverses obesity
It is well known that neovascularization (angiogenesis, 
formation of new blood vessels) and adipogenesis (for-
mation of new fat cells) are temporally and spatially cou-
pled processes [6, 7, 54]. Due to its plasticity and constant 
remodeling, the WAT is highly vascularized and depends 
on an extensive blood supply systems (vasculature) for 
sustained growth and expansion [54]. During develop-
ment of obesity, the tissue expands by both hyperplasia 
of preadipocytes and hypertrophy of adipocytes [54, 55]. 
As the tissue continues to grow, it triggers the release 
of pro-angiogenic factors that promote extension of the 
pre-existing blood vessels towards the diseased cells in 
order to supply the tissue with nutrients and oxygen [6, 
Fig. 1 Impact of obesity on the body’s homeostasis. Obesity causes WAT dysfunction and alters adipokine expression. Changes in adipokine 
expression in the WAT, affect the activity of other organs (brain, liver and muscles)
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54]. This occurs through a process called angiogenesis. 
Regulating WAT growth by targeting its vasculature with 
anti-angiogenic inhibitors is therefore a feasible strategy 
to treat obesity [6, 54, 55]. Pro-angiogenic factors that 
were identified in the WAT as targets for the treatment 
of obesity and therapeutic intervention include vascular 
endothelial cell growth factor (VEGF), fibroblast growth 
factor, angiopoietin, leptin, platelet derived growth fac-
tor, matrix metalloproteinases, cathepsin D, hepatocyte 
growth factor [7, 54], and PHB [11, 54]. Unlike in the 
WAT where angiogenesis promotes energy storage, angi-
ogenesis is essential for BAT hyperplasia for the rapid 
cell division of brown fat precursor cells and endothelial 
cells for energy expenditure [6, 7]. Therefore, it is crucial 
that anti-angiogenesis treatment be targeted in order to 
avoid bystander effects, because angiogenic components 
involved in adipogenesis are also critical to many other 
biological processes [6, 7].
PHB has shown potential as a WAT vascular marker 
[11]. Although the protein is expressed in various cel-
lular compartments [56, 57], it is highly expressed as a 
cell surface receptor in the vasculature of the WAT in 
diet-induced animal models of obesity and humans [11, 
13–15]. As such, PHB can be used for targeted delivery 
of cytotoxic agents to vascular endothelial cells inhibit-
ing angiogenesis in the WATs and reverse obesity (Fig. 2) 
[11, 57]. Molecules that bind to PHB with high specificity 
have been identified through phage display [11, 57], 
among them the CKGGRAKDC peptide has been used 
in various obesity models [11, 13–15]. This peptide will 
be referred to as adipose homing peptide (AHP) [15]. 
Systemic injection of AHP conjugated to a pro-apop-
totic D(KLAKLAK)2 peptide (AHP-KLA, adipotide) in 
diet-induced obese mice [11] and monkeys [53] resulted 
in significant body weight loss and reversal of obesity. 
The chimeric peptide (AHP-KLA) was able to bind to 
PHB receptor overexpressed by the endothelial cells in 
the WAT vasculature of obese subjects (Fig.  2a). AHP-
KLA was internalized by receptor mediated endocyto-
sis, and once inside the cells the KLA peptide disrupted 
the mitochondrial function and caused cytochrome C 
release. Cytochrome C triggered caspase-3 activation 
that resulted in cell death through the intrinsic apop-
totic pathway. Consequently, the treatment normalized 
the WAT vasculature (Fig. 2b), the metabolic activity of 
the animals and reduced body weight (Fig.  2c) [11, 53]. 
The body weight loss was attributed to the reduced WAT 
mass (Fig. 2d) in both the visceral and subcutaneous fat 
depots [11]. Therefore, targeting the WAT vasculature 
could potentially be used to treat obesity and its medical 
consequences. However, chimeric peptides are prone to 
degradation and higher dosage will be required to attain 
efficacy at the target tissue or organ [11]. Moreover, 
long term systemic circulation may also cause unwanted 
Fig. 2 Reversal of obesity using PHB-targeted pro-apoptotic agent. The WAT is highly vascularized, during development of obesity it expresses 
pro-angiogenic markers that can serve as a target for treatment of obesity (a). Targeting the WAT vasculature of obese mice with AHP-KLA 
reduced vascularization associated with obesity (b). This was accompanied by reductions in body weights (c) and WAT mass (d). Reproduced with 
permission [11]. Copyright 2014, Nature journals
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immune responses and produce antibodies against the 
chimeric peptide, thus causing reduction of the desired 
efficacy.
To overcome the protein degradation, immune 
response and dosage hurdles, nanotechnology-based 
strategies were developed. Nanotechnology is defined 
as the development of materials with a size of ≤ 100 nm 
[57, 58]. Various types of nanoparticles (NPs) have been 
developed for a number of applications in environmental, 
energy, water and medical sectors. The choice of nano-
material is dependent on the intended application. At a 
nanometer scale, the NPs portray unique physico-chem-
ical properties compared to their bulk counterpart [58–
60]. These properties contribute to the novel applications 
of the nanomaterials in different sectors. In biomedical 
research, the NP size can be exploited as multimodal 
systems which allow attachment of multiple molecules 
on their surface due to their larger surface area [59, 60]. 
Various NPs for biomedical applications range from lipid 
based, polymeric and metallic nanomaterials [61]. The 
specificity and drug efficacy can be enhanced by attach-
ing targeting molecules (antibodies, aptamers, peptides) 
that recognise disease-specific biomarkers. Therapeutic 
agents (drugs), and imaging agents to monitor disease 
response to the treatment can also be attached in the 
same NPs [62]. Targeted nanotherapy has demonstrated 
improved therapeutic index, ability to discriminate 
between diseased and healthy tissues, and a potential to 
maximize the safety and efficacy of the drugs [13, 14, 62]. 
Independent studies have reported the feasibility of PHB-
targeted NPs to target [13–15, 63] and inhibit angiogen-
esis in the WAT of diet-induced animal models of obesity 
[13, 14].
Targeted delivery and biodistribution of PHB‑NPs
The specificity and biodistribution of gold NPs (AuNPs) 
[15] and quantum dots (QDs) [63] were demonstrated 
in a diet-induced obese Wistar rats. The rats were intra-
venously injected with a single dose of either untargeted 
(peptide-free AuNPs [15] and QDs [63]) or PHB-targeted 
NPs (AHP-AuNPs [15] and AHP-QDs [63]), and sacri-
ficed 24  h post-injection. Analysis of tissues by induc-
tively coupled plasma optical emission spectroscopy 
(ICP-OES) (Fig.  3) showed the selectivity of the AHP-
AuNPs for PHB-expressing tissues (WATs) while the 
peptide-free AuNPs accumulated mostly in the reticu-
loendothelial system (RES) organs such as liver, lungs, 
spleen, kidney [15]. Similar observations were made with 
the QDs (Fig.  4), where the fluorescent signal of AHP-
QDs was detected in the WATs, and that of the free QDs 
was observed in the RES organs using Xenogen imaging 
system [63].
The two studies substantiated that metallic NPs can 
be delivered into the target tissues, serving as effective 
drug delivery [15], as well as imaging systems [63] with-






























Fig. 3 Biodistribution of AuNPs in tissues and organs collected from diet-induced obese Wistar rats. AHP-AuNPs accumulated in PHB expressing 
tissues (WATs) 24 h post injection, while the untargeted AuNPs mostly accumulated in the RES organs. Reproduced with permission [13]. Copyright 
2015, Springer. PBS phosphate buffered saline, GNP gold nanoparticles, AHP adipose homing domain, SQ subcutaneous, Mes mesenteric, Epi 
epididymal, Retro retroperitoneal, Peri perirenal, WATs white adipose tissues
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findings were further validated on PHB-expressing cells, 
the breast (MCF-7) and colon (Caco-2) cancer cell lines, 
which were reported to express PHB as a cytosolic and 
extracellular receptor, respectively [15, 62]. These cells 
demonstrated the sensitivity and specificity of the PHB-
targeted AuNPs containing KLA pro-apoptotic molecules 
(AHP-AuNP-KLA) as a treatment, whereby the targeted 
nanotherapy induced a significant anti-proliferative 
activity on the cells that express the receptor for AHP on 
the cell surface (Caco-2 cells). The therapeutic activity of 
the KLA peptide was retained and enhanced following 
conjugation to AuNPs through receptor mediated target-
ing, and demonstrated differential uptake by Caco-2 cells 
(cells that express PHB on the cell surface). Thus, tar-
geted therapy could be a plausible strategy for treatment 
of chronic diseases including obesity [63].
Fig. 4 Biodistribution of QDs in diet-induced obese Wistar rats tissues and organs. AHP-QDs accumulated in PHB expressing tissues (WATs) 24 h 
post injection, while the untargeted QDs mostly accumulated in the RES organs. Reproduced with permission [63]. Copyright 2018, Dove Medical 
Press. QD quantum dot, AHP adipose homing domain, SQ subcutaneous, Mes mesenteric, Epi epididymal, Retro retroperitoneal, Peri perirenal
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Anti‑angiogenic effects of PHB‑targeted nanotherapy
Angiogenesis plays a crucial role in the pathogenesis and 
progression of obesity, hence, strategies that can inhibit 
angiogenesis in the WATs could potentially be able to 
reverse obesity. Targeting fat depots using angiogenesis 
inhibitors (e.g. TNP-470, angiostatin, and endostatin) 
reduces body weight [6, 11, 54, 55], providing validation 
that anti-angiogenic strategies may be a useful anti-obe-
sity therapeutic approach. Preclinical animal studies dem-
onstrated anti-obesity effects of AHP-KLA biconjugate 
in obese mice [11] and monkeys [53], these effects were 
improved by using nanotechnology-based delivery sys-
tems [13–15]. The PHB-vascular targeted nanosysems 
had reproducible results using various types of nanoma-
terials such as AuNPs, QDs, liposomes, and polymeric 
NPs [13, 15, 63]. The mechanism of action of either metal-
lic or biodegradable NPs in obese subjects is summarized 
in Fig. 5. After intravenous injections, the NPs localize to 
the endothelial cells by binding to the PHB receptor in 
the WAT vasculature. Once inside the cells, the KLA pep-
tides on the surface of the metallic NPs are free to interact 
with cellular organelles while the ones encapsulated in the 
biodegradable NPs will rely on the cellular environment to 
trigger its release. This is followed by induction of apop-
tosis in the endothelial cells by the KLA peptides which 
then results in reduced WAT mass and total bodyweight. 
Disrupting the blood supply to the WAT starves the adi-
pocytes, forcing them to metabolize the excess energy 
possibly through lipolysis. Another assumption could be 
through adipocyte cell death since not enough oxygen can 
reach these cells [13, 14].
The nanocarriers significantly enhanced the potency of 
the therapeutic peptide (KLA), increased drug uptake and 
accumulation in the target site by either enhanced perme-
ability and retention (EPR) effect [13] or receptor-medi-
ated targeting [13, 14]. This dual-targeting mechanism 
was investigated by comparing the activity of untargeted 
NPs (KLA-liposomes) against that of PHB-targeted nan-
otherapy (AHP-KLA liposomes) on obese mice. PHB-
targeted nanotherapy was developed by encapsulating 
KLA peptides in liposomes, and attachment of AHP on 
the NP surface. KLA-liposomes used passive targeting 
based on the tissue’s EPR effect [13], whereas AHP-KLA 
liposomes bound to the PHB receptor and entered the 
Fig. 5 Mechanism of PHB-targeted nanotherapy for reversal of obesity in diet-induced obese rats. The targeted NPs will bind to the PHB receptor 
on the cell surface. Once the nanomaterials are internalized, the therapeutic peptide will trigger cytochrome C release from the mitochondria, 
followed by caspase activation then cell death through apoptosis. NP(s) nanoparticle(s), PHB prohibitin, WAT white adipose tissue
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cells via active targeting. Both systems managed to target 
and destroy WAT angiogenic blood vessels, resulting in 
reduced body weight. Postmortem analysis revealed that 
weight loss was due to decreased mass in the subcutane-
ous (inguinal) and visceral (epididymal) fat depots. The 
nanosystems, in addition to their anti-obesity effects, 
showed potential for prevention of obesity-induced met-
abolic diseases. The animal ‘s metabolic functions were 
normalized by reduction of the ectopic fat accumulation 
in the liver and muscles [13, 14]. Moreover, the nanosys-
tems were also biocompatible and showed no indication 
of toxicity after 4  weeks of treatment [14]. When com-
pared to AHP-KLA (3  mg/kg body weight), at a three-
fold lower dose of untargeted and PHB-targeted KLA 
liposomes (1 mg/kg body weight) the anti-obesity effects 
were significantly enhanced. Another advantage of using 
the nanosystems was that more drugs can be incorpo-
rated in one NP, while the chimeric peptides deliver one 
KLA peptide per one AHP molecule. Furthermore, drug 
release from the NPs can be controlled and have longer 
circulation time and prolonged release [14].
Transformation of WAT into BAT increases thermogenesis
The function of BAT as an energy dissipating organ is 
well established, together with its ability to produce heat 
energy and increase thermogenesis (energy expenditure) 
[3, 35, 39, 42, 43, 64]. The recent appearance of beige or 
brown-like adipocytes in WAT depots of adult humans 
has sparked interest to use thermogenic activity for obe-
sity treatment [38, 45]. This has led to exploration of 
WAT browning as a target for obesity treatment [39, 42, 
43, 64]. Hence, strategies that can stimulate the uncou-
pled respiration rate and thermogenesis through reacti-
vation of BAT or transformation of WAT to BAT could 
provide alternative approaches for treatment of obesity 
and its comorbidities [23, 38, 40, 44, 64].
The brown-like (beige or brite) adipocytes detected in 
human WAT behave and function like the brown adipo-
cytes [38, 42, 43]. Their UCP-1 levels and mitochondrial 
content are comparable to those of brown adipocytes; 
and through uncoupled mitochondrial respiration, the 
beige adipocytes can also burn fat and generate heat, 
increase energy expenditure and reduce body weight [23, 
38, 44, 64]. WAT browning can be induced through two 
main mechanisms, either by control of environmental 
temperature (cold exposure) or sympathetic nerve inner-
vation (β-adrenergic signaling) [23, 64]. Cold exposure-
related browning occurs as an adaptive response through 
non-shivering thermogenesis. After prolonged exposure 
to cold temperatures (4–16 °C) in experimental settings, 
the body attempts to sustain the core temperature by 
increasing its metabolic activity [46–48]. At this state, 
transcription factors (peroxisome proliferator-activated 
receptor (PPAR) γ and α, PPARγ-coactivator-1α and 
PR domain-containing protein 16) that are involved in 
uncoupled respiration become activated, which then trig-
ger WAT browning by increasing the UCP-1 expression 
[38, 46, 47]. Natural cold exposure-related browning is 
mediated by sympathetic nervous system through norepi-
nephrine signaling. Norepinephrine, secreted by the post-
ganglionic sympathetic neurons binds to β-adrenergic 
receptor and initiate cold-induced thermogenesis [38, 41, 
47]. β-adrenoceptor agonists have been used in browning 
of both subcutaneous and visceral WAT depots. How-
ever, these receptors are also found in the gastrointestinal 
tract, prostate and bladder [23, 65] and its variants in the 
heart and kidneys [23]. And more specific agonists will be 
required to avoid off target browning.
WAT Browning agents
Various agents capable of inducing WAT browning have 
been reported, and only the three highlighted in Table 1 
will be discussed in this review. They are currently used 
as treatment for diseases other than obesity, and their 
browning activity is now explored as a possible anti-obe-
sity treatment.
Dibenzazepine induce WAT browning by inhibiting Notch 
signaling pathway
Dibenzazepine (DBZ) is an iminostilbene. Drugs in this 
category are used as anti-depressants, mainly for treat-
ment of schizophrenia [17]. It exerts its actions by block-
ing the activity of γ-secretase, leading to inhibition of the 
Notch signaling pathway. Notch signaling is very crucial 
in the development of embryos, tumorigenesis, vascu-
lar remodeling, and determines the fate of stem cells. 
Dysregulation in this process has been implicated in the 
development of inflammatory diseases [67]. Notch sign-
aling activity is extremely high in pathological WATs 
associated with metabolic syndrome, especially in obe-
sity, diabetes and CVDs [68]. Therefore, suppression of 
Notch signaling has beneficial health effects against a 
wide range of metabolic and inflammatory diseases [17, 
67].
The role of Notch signaling in obesity is still elusive 
[64], however some studies have shown that inhibition of 
this process in the WAT by a γ-secretase inhibitor (DBZ), 
reverses obesity and improves metabolic functions [17, 
64]. DBZ induced anti-obesity effects by transforming 
the WAT to BAT [64]. However, the use of free DBZ can 
be accompanied by side effects, as failure to deliver the 
drug at the target location will cause biogenesis of brown 
adipocytes and inhibition of Notch signaling in all cells 
they come into contact with [17]. These undesirable 
effects might induce development of secondary diseases 
[64]. Local delivery of DBZ to target tissues was achieved 
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by using poly(lactide-co-glycolide) (PLGA) NPs as drug 
delivery agents. Encapsulation of DBZ in PLGA NPs 
improved its targeting and led to localization of the drugs 
on target tissues. Three days post intraperitoneal injec-
tion of the DBZ-loaded NPs directly into the subcutane-
ous WAT depot, the untargeted NPs were retained at the 
site of injection. Although the NPs managed to spread 
throughout the local tissue, no NPs were detected in 
other tissues including the RES organs. Using this carrier 
system confined the DBZ browning effect only in the tar-
get tissue, enhanced energy expenditure and prevented 
weight gain in the diet-induced obese mice. The meta-
bolic activities of the animals were also normalized as 
evidenced by reduced blood glucose, cholesterol, insulin, 
TAGs and free fatty acids [17]. The improvement in insu-
lin sensitivity and glucose tolerance in the animals, sug-
gest that the browning effect through nanosystems can 
also be used for treatment of metabolic syndrome [17].
Resveratrol‑induced WAT browning
Resveratrol (3,5,4′-trihydroxy-trans-stilbene, Res) is a 
natural polyphenolic compound mostly found in grape 
skins and red wine, although it can also be produced by 
other plants such as berries and peanuts [38, 68]. It is a 
phytoalexin produced by plants in response to attacks 
by either bacteria or fungi as a defense mechanism. Its 
health benefits as an antioxidant, include protection 
against CVDs, cancer, diabetes, and Alzheimer’s disease 
[69]. It is also used as one of the main components in 
the Kojo-kon medicine, a traditional medicine used in 
the treatment of heart and liver diseases. It has earned 
its market name of the “French paradox” because it has 
shown low incidences of heart diseases among French 
people who indulge in high fat diets [68, 69].
Of interest, Res is one of the potential anti-obesity 
drugs currently in phase II clinical trials [23, 70]. The 
preclinical anti-obesity effects of Res have been reported, 
which are mainly attributed to its ability to regulate adi-
pocyte differentiation, lipolysis, mitochondrial biogenesis 
and fat acid oxidation [71, 72]. Other studies also dem-
onstrated that Res administration can enhance expres-
sion of BAT genes such as UCP-1 and CD137, suggesting 
that it is responsible for transformation of WAT into BAT 
or beige-like adipocytes, leading to increased energy 
expenditure and reduced body weight [44, 71, 73]. An 
independent study demonstrated the synergistic effect 
of Res as a food supplement. Incorporating stilbene syn-
thase (Res biosynthesis gene) in Dongjin rice through 
recombinant DNA technology improved the endogenous 
anti-obesity effect of the rice [74]. However, Res has poor 
solubility in water (< 1  mg/mL), is prone to undergoing 
metabolic transformation (methylation or glucoronida-
tion) in the liver, and has high metabolism in humans 
which reduce its stability, bioavailability and activity 
[73–77].
Various types of nanosystems can used as delivery 
system to increase Res’s bioavailability and stability. 
Encapsulation of Res in lipid nanocarriers and liposomal 
delivery systems was able to increase its solubility, distri-
bution and bioavailability in vitro studies. Res is sensitive 
to light and high temperatures. The lipid nanocarriers 
have been shown to mask the drug (Res) from degrada-
tion and prolonged its release. The browning activity of 
Res-loaded NPs on 3T3-L1 adipocytes was retained as 
evidenced by the increase in expression of beige (CD137) 
and brown adipocytes markers (UCP1, PPARγ co-activa-
tor 1α), coupled with reduced expression of white adipo-
cytes markers (insulin-like growth factor-binding protein 
3) [66, 76]. Similar effects were achieved by Res-loaded 
PLGA NPs for treatment of non-alcoholic fatty liver dis-
ease. Both the empty vehicle and Res-loaded PLGA NPs 
were biocompatible and showed no toxicity towards the 
HepG2 cells during the 24  h test period. Interestingly, 
the NPs accumulated in an in vitro model of oleic acid-
induced hepatic steatotic (HepG2) cells, inhibited lipid 
accumulation and lipogenesis, while enhancing lipolysis 
[78]. An independent study also showed the potential 
of self-nano-emulsifying drug delivery system to protect 
Table 1 The actions and limitations of WAT browning agents
Browning agents Actions Limitations Current application Refs
Dibenzazepine γ-Secretase inhibitor
Inhibit Notch signaling









High metabolism in humans
CVDs [23, 66]
Rosiglitazone PPAR gamma activator Hydrophobic
Solubility
T2D [12]
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and enhance the bioavailabilty and pharmacokinetics of 
Res oral formulation [79]. For clinical applications, Res as 
a multifunctional compound presents a major challenge 
due to lack of specificity, and its multiple actions on adi-
pocytes [73], hepatocytes [78], cardiomyocytes [69], etc. 
In order to improve its specificity, the attachment of tar-
geting molecules can be used to restrict its functions to 
target cells. This was further demonstrated by attaching 
transferrin antibodies on solid lipid NPs loaded with Res. 
The targeted NPs selectively bound and accumulated on 
the endothelial cells, these cells express transferrin recep-
tors and used as a human blood brain barrier model for 
Alzheimer’s disease [77].
Rosiglitazone promotes WAT browning by activating PPARγ
Thiazolidinediones (TZDs) such as troglitazone, piogl-
itazone, and rosiglitazone (Rosi) are potent anti-diabetic 
agents. TZDs bind to the nuclear peroxisome prolifera-
tor-activated receptor (PPAR)-γ, subsequently activating 
genes that encode proteins involved in the metabolism 
of glucose and lipids. This leads to an increase in glucose 
uptake in skeletal muscle and adipose tissue, reduction 
in hepatic glucose output, and finally, an increase in free 
fatty acid uptake. Besides their anti-diabetic potency, 
these TZDs have anti-inflammatory effects on vascu-
lar cells. Rosi is TZD, currently used as an anti-diabetic 
drug alone (Avandia®) or in combination with either 
metformin (Avandamet®) or glimepiride (Avandaryl®). 
Health effects of Rosi include anti-inflammatory effects, 
enhanced insulin sensitivity [80, 81], and anti-Alzhei-
mer activity [82]. PPARγ is a nuclear transcription fac-
tor expressed in the WATs, pancreatic β cells, vascular 
endothelium, and macrophages [81, 83]. In the WAT, it 
is involved in adipocyte differentiation, fatty acid uptake 
and storage, and glucose uptake. Rosi has a number of 
side effects that are observed in at least 5% of patients, 
which include upper respiratory tract infection, head-
ache, edema, weight gain, risk of heart attack and death 
[81].
Despite its contradictory effect of increasing body 
weight in diabetic patients [83, 84] Rosi was also reported 
to have anti-obesity effects resulting from its ability to 
induce WAT browning [12, 16, 85], which in turn acti-
vate angiogenesis, increase mitochondrial biogenesis 
and cause weight loss in rodents. As such, Rosi showed 
potential as an anti-obesity drug. Rosi blocks the actions 
of tumor necrosis factor (TNF)-α in the WATs, as a 
result increases adipocyte differentiation (adipogenesis) 
and reduce release of free fatty acids from adipocytes 
[81, 83]. Rosi is administered orally, and while it is eas-
ily absorbed, the majority of the drug tend to bind to 
blood proteins, thus reducing its efficacy. Since most of 
the drug is metabolized by the cytochrome P-450 2C8 
isozyme, and excreted in the urine [81], higher dosages 
of the drug is required to reach the target tissues. Inter-
estingly, nanocarriers can control the rate at which the 
drugs are released by making them sensitive to certain 
physiological parameters such as pH, enzymes, and tem-
perature, in order to trigger drug release once they are 
inside the cells. This was demonstrated by encapsulating 
Rosi on polymeric [12] and glucose-responsive dextran 
[16] NPs as discussed below.
Rosi‑NPs stimulate angiogenesis and enhance WAT browning
Inhibition of angiogenesis in the WATs enhances lipolysis 
and reduces body weight [11, 13, 14, 54], while the oppo-
site occurs when using the strategies that reverse obesity 
by stimulating energy expenditure [12]. Active angiogen-
esis is crucial for highly thermogenic cells, which in the 
WATs can lead to tissue browning and body weight loss. 
Rosi has dual functions in the reversal of obesity: stimula-
tion of angiogenesis and transformation of WATs. These 
effects are confirmed by reversal of obesity through vas-
cular targeted Rosi NPs. Polymeric NPs (made up of 
PLGA-b-PEG copolymer) were used to deliver Rosi in 
order to reduce the bystander effects and enhance its 
efficacy. The Rosi-encapsulated NPs were localized in 
the WAT vasculature and increased specificity by target-
ing PHB or  integrinαv receptors using AHP and iRGD 
(CRGDK/RGPD/EC) targeting peptides, respectively. 
The targeting peptides recognize angiogenic receptors in 
the WATs. The iRGD peptide is a dual-targeting peptide 
that is further cleaved into the CRGDK fragment after 
binding to integrin receptors. CRGDK peptide fragment 
then bind to neuropilin-1 in the local tissue and enable 
delivery, entry and uptake of the NPs with its cargo. Mice 
treated with the vascular targeted-Rosi NPs showed sig-
nificant weight loss compared to the ones treated with 
the free Rosi and untargeted NPs. Weight loss was attrib-
uted to the enhanced WAT browning and angiogenesis, 
as confirmed by increased levels of BAT (UCP-1, tran-
scriptional coactivator Cidea, type 2 deiodinase), and 
endothelial cell angiogenic (CD31, Isolectin B4) markers. 
Treatment with Rosi-NPs led to phenotypic changes in 
the inguinal and epididymal WATs, which includes color 
changes (reddish vasculature and brown adipocytes), 
reduced adipocyte size, and condensed cellular contents. 
The targeted Rosi NPs reduced the levels of cholesterol, 
TAGs, and insulin in the blood, effects which were not 
detected in mice treated with free drug (Rosi) or untar-
geted NPs [12].
Transcutaneous delivery and WAT browning effects 
of a microneedle Rosi‑NPs patch
A non-invasive microneedle patch was used as a trans-
dermal delivery agent for Rosi-NPs to the subcutaneous 
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WAT. The patch was composed of a drug (Rosi), glucose 
oxidase and catalase which were encapsulated into bio-
degradable acid-sensitive dextran NPs. Glucose oxidase 
was used to convert host glucose into gluconic acid and 
hydrogen peroxide  (H2O2), thus creating an acidic envi-
ronment for drug (Rosi) release. Catalase was used to 
remove the byproduct  (H2O2) of the glucose oxidase 
reaction. The NPs were then embedded in a polymeric 
microneedle array patch, made of hyaluronic acid (HA) 
to enable entry through the skin [16]. HA can pass 
through the skin’s protective layer, the stratum corneum, 
which protects internal tissues against desiccation, infec-
tion, xenobiotic chemicals, and mechanical stress. In so 
doing, HA can deliver drugs into the subcutaneous layer 
[86] and bloodstream [87]. It is used topically for trans-
dermal drug delivery of poorly bioavailable therapeutic 
agents [87, 88], and has been successfully used in trans-
porting various molecules including growth factors, 
interferon and anticancer drugs [87, 89].
The therapeutic potential of the microneedle patches 
was assessed on diet-induced obese mice. The Rosi-NP 
patches were placed on one side of the inguinal tissue and 
an empty patch was placed on the other side of the mice 
(Fig. 6). The glucose-responsive Rosi NPs locally induced 
subcutaneous WAT browning in the obese mice, which 
was affirmed by overexpression of BAT markers (UCP1, 
Dio2, Elovl3, Cidea, PPARγ co-activator 1α, cytochrome 
c oxidase subunit (Cox) 7a1, and Cox8b. The localization 
and transdermal delivery of Rosi-NPs was accompanied 
by phenotypic changes in the target tissues, metabolic 
changes and weight loss. The study demonstrated that 
transcutaneous delivery systems could be as effective and 
produce a comparable therapeutic effect in  vivo as the 
other two strategies that were described earlier. It also 
presents a more favorable and desirable delivery strategy 
as it is non-invasive, painless and does not require trained 
personnel to administer treatment. In addition to body 
weight loss through localized browning of the inguinal 
WAT, the treatment also reduced visceral WAT, reduced 
interleukin-6 inflammatory marker and enhanced meta-
bolic activities [16].
Fig. 6 Transformation of subcutaneous WAT into BAT using transcutaneous microneedle Rosi-NP patches. Rosi-NP were prepared by encapsulating 
Rosi, glucose oxidase (GOx) and catalase (CAT) in pH responsive dextran NPs coated with alginate. The glucose-responsive dextran NPs (Rosi NP) 
reduced animal bodyweight through browning of WAT by encapsulated Rosi, these effects were comparable to a potent thermogenic activator (CL, 
CL 316,243). The difference was statistical significant compared to rats subjected to empty vehicle patches (EV). Reproduced with permission [16]. 
Copyright 2017, American Chemical Society
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Nanotechnology‑based photothermal lipolysis
Photothermal therapy (PTT) involves the use of photo-
thermal agent which can be excited by a laser to gener-
ate heat energy that in turn destroy and kill malignant 
cells. PTT-induced cell death occur via two major path-
ways either by necrosis or apoptosis [90]. During necro-
sis, the heat disrupts the plasma membrane, causing cell 
burst and leakage of cellular components. This results in 
inflammation and damage to the surrounding cells/tis-
sues [90]. Apoptosis on the other hand, occurs in a con-
trolled manner with reduced inflammatory activities, and 
therefore more desirable for clinical application [91].
Metallic NPs are effective photothermal agents as they 
can convert visible or near infrared (NIR) light into heat 
after excitation by laser, and destroy target cells [90, 92–
94]. Figure 7 presents a nano-based PTT mechanism for 
imaging and destruction of cancer cells, and an alterna-
tive carrier free nanodrug system that can deliver thera-
nostic agents to target cells. This system eliminates the 
uncertainties surrounding the fate of inorganic materials 
in living systems, as it uses the self-assembly chemother-
apeutic drug as a delivery system. In this particular study, 
a NIR fluorescent dye (indocyanine green) was loaded 
in ursolic acid self-assembly nanodrug. The carrier-free 
nanodrug conjugate through lactobionic acid on its sur-
face, was selectively targeted at cancer cells that express 
asialoglycoprotein receptor. Indocyanine green is the 
only FDA-approved photosensitizer for clinical use. Its 
application is limited by poor solubility and short half-life 
[95].
Metallic NPs as photosensitizing agents are stable, pho-
tostable, biocompatible, and non-toxic. As such, metallic 
nanomaterials holds a great promise for PTT [90, 92–94]. 
Their shapes play a crucial role in PTT, and can be used 
to induce selective cell death [94]. Different NP shapes 
(nanospheres vs nanorods) absorb and emit light differ-
ently, and these parameters can potentially be used to 
regulate the switch between necrosis and apoptosis [94]. 
Gold nanosphere (AuNS)-induced PTT is suitable for 
shallow cancers (e.g. skin cancer) [96], and has demon-
strated localized photothermolysis of target cells in vitro 
and in vivo [91, 97–99]. Although visible light is success-
ful to some extent in destroying diseased or malignant 
cells that accumulate the AuNSs, the need for radiation 
to penetrate deep into tissues is desired for the clinical 
application of PTT. NIR external radiation is capable of 
achieving this, as it can penetrate soft tissues up to 10 cm 
at the NIR tissue transmission window of 650–900  nm 
[100]. By changing the shape and composition of NPs 
from spherical to rod-shaped, the surface plasmon reso-
nance (SPR) is shifted into the NIR transmission win-
dow [96, 101]. Attaching targeting molecules on gold 
nanorods (AuNRs) enhanced localization into target 
cells, reduced exocytosis, and toxicity in  vivo [91]. The 
nanosystems could be effective photosensitizers in nano-
based PTT for treatment of chronic diseases and provide 
an alternative platform for translation into clinical use.
The benefits of PTT have been explored for obesity 
treatment. Obesity results from expansion of WATs due 
to uncontrollable proliferation of adipocytes in various 
Fig. 7 Nano-based PTT for treatment and imaging of diseases. The carrier-free self assembly nanodrug conjugate selectively accumulated in the 
diseased site after intravenous administration of the nanodrug conjugate, and induced cell death following PTT after laser exposure. Reproduced 
with permission [95]. Copyright 2018, Elsevier. PDT photodynamic therapy, PTT photothermal therapy, ASGPR Asialoglycoprotein receptor
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WAT depots, therefore its treatment requires removal/
resection of the diseased cells/tissue. This strategy has 
worked well for removal of tumor tissues [91]. In obe-
sity, laser-assisted liposuction and laser radiation are 
among the procedures that have been used to reduce 
WAT mass by taking out excess fat from subcutaneous 
and visceral WAT depots. Laser radiation demonstrated 
selective photothermolysis of WAT in vitro as well as in 
human subjects. Humans were subjected to a 1210  nm 
laser directly to their abdomens, followed by collection of 
biopsies the first 3 days and at 4–7 weeks of laser treat-
ment. The biopsies showed laser induced damage of the 
tissue. This study demonstrated the potential use of laser-
based lipolysis for reduction of fat within the WAT, and 
for treatment of obesity [102]. However, these proce-
dures are highly invasive, uncomfortable, painful, takes a 
long time to recover, causes deformities, and lumpy skin 
due to seromas [18, 19, 102]. These procedures can be 
improved through the use of nano-based thermal agents 
to reduce discomfort, and laser-induced tissue damage.
Photothermal lipolysis of WAT: effect of AuNSs vs AuNRs
Metallic NPs have shown potential for photothermal 
lipolysis of adipocytes in the WAT of diet-induced obese 
mice. AuNSs and AuNRs can absorb visible and NIR light 
and convert it to heat energy by SPR, and destroy target 
cells. The fat tissues have different thermal relaxation 
rates to its surrounding environment, and so this allows 
for rapid and localized heating only in the WAT depots 
[19, 103]. The WATs that have accumulated the NPs will 
heat up faster, and dissipate heat slower than water, due 
to its lower specific heat capacity and thermal conduc-
tivity. Heating by this mechanism selectively softens and 
loosens the WAT, facilitates removal of excess fat with 
minimal trauma. Only the target tissues, where the NP 
solution is infused, it will absorb laser energy, therefore, 
minimizing the potential damage to the surrounding tis-
sues [19]. The heat energy generated from the NPs does 
not radiate any form of energy which might be toxic to 
the human body. Hence, metallic NPs might provide a 
safer and healthier PTT for patients than other sorts of 
targeted radiation techniques that are used for diseases 
such as cancer [99].
The nano-based systems are especially interesting 
due to their increased loading capacity, and potential 
for attaching multiple molecules. Their physico-chem-
ical properties can be altered by attaching various mol-
ecules on the NPs. For instance, a dual targeted hollow 
AuNSs were able to pass through the three layers of the 
skin non-invasively, and through PTT, was able to induce 
adipocyte cell death in mice [18]. Hyaluronic acid (HA) 
attached to the hollow AuNSs allowed transdermal 
delivery of the NPs to the target tissue. The hyaluronate 
hollow AuNSs were functionalized with AHP to target 
PHB once they reach the vasculature of the subcutaneous 
WAT. The NPs were topically applied on the abdominal 
region of diet-induced obese mice, transdermal delivery 
was assessed by photoacoustic imaging. As shown in 
Fig. 8 [18], the NPs were able to pass through the stratum 
corneum and dermis, and localize in the subcutaneous 
tissue. After just an hour, a signal for PHB-targeted NPs 
was reduced significantly compared to untreated ani-
mals. The disappearance of the photoacoustic signal was 
associated with the death of the adipocytes treated with 
hyaluronate hollow AuNSs. Although the study might 
have been terminated after 2  h of treatment (authors 
did not specify), there is clear evidence that these NPs 
can be used to induce PTT for reduction of WAT mass 
and reversal of obesity. It would have been interesting 
to follow up on the animal body weight after treatment. 
Nonetheless, the study presents an opportunity for the 
non-invasive transdermal delivery of PTT agents in the 
WATs [18].
An independent study reported on the effects of 
NanoLipo, a AuNR solution injected on the abdominal 
tissue of Yucatan mini pigs. When exposed to NIR laser, 
NanoLipo was able to uniformly and selectively heat up 
the WATs while sparing the surrounding tissues. The 
AuNR solution used in this study absorbs light at 800–
900 nm which is within the tissue transparency window, 
while the endogenous chromophores (water and hemo-
globin) have lower absorption and the FDA-approved 
laser-assisted liposuction is at ≥ 1000 nm. Laser-assisted 
liposuction involves insertion of laser probes into the sub-
cutaneous tissue to liquefy small volumes of fat because 
water absorbs and emits heat at the same wavelength. 
As a result the surrounding tissues, including muscles 
and fibrous connective tissues, are also affected by the 
heat. NanoLipo uses external laser which only affects 
the abdominal tissues in which the AuNRs are localized, 
this enhances the selectivity and safety of the treatment. 
The procedure was well tolerated, swelling healed faster, 
the NRs are easily aspirated as they do not bind to the 
WATs, and the AuNR dosage used (0.01–0.05 g/kg body 
weight) is below the expected toxicity limit (3.2 g/kg) for 
gold. NanoLipo was able to remove double the fat con-
tent within a short period when compared to the conven-
tional suction-assisted lipectomy [19].
Biomedical application of nanotechnology
Nanotechnology has revolutionized the field of medicine, 
with the promise of safer and more selective drug formu-
lations. NPs have unique properties that can be manipu-
lated for biological applications, due to their small size 
and large surface area, they can be used for multimodal 
applications [58, 60, 62, 104]. These properties allow for 
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attachment of multiple molecules on a single particle, 
creating biocompatible multimodal systems for diagnosis 
and treatment of diseases. The nanocarriers (liposome, 
metallic NPs, polymeric NPs) can be easily modified with 
targeting molecules (such as peptides, antibodies, aptam-
ers, etc.) to achieve specificity and selectivity, and thera-
peutic molecules (drugs) for targeted disease treatment 
[59, 60], as well as imaging agents to monitor the disease 
response to treatment in real time [58]. By manipulat-
ing the NP’s physico-chemical properties (size, shape 
and surface chemistry), the interactions of the NPs with 
the biological systems, biodistribution and their clear-
ance by the RES can be controlled [105]. A change in 
these parameters can significantly influence the phar-
macokinetics of the nanoformulations, circumvent drug 
limitations by increasing drug stability, circulation time, 
prevent biodegradation, and control drug release. NP 
size is fundamental in determining the rate at which 
NPs are cleared by the body’s RES organs and mononu-
clear phagocyte system. Size also facilitate NP uptake by 
penetrating highly impermeable cellular barriers; thus, 
improving the delivery and efficacy of the drug to its spe-
cific target [106].
Nano‑based drug formulations in clinical practice
Nanomedicine refers to the application of nanoscience 
and nanotechnology in medical sciences, for treatment, 
diagnosis and imaging purposes [58]. A number of nano-
based formulations are either available for human use as 
FDA-approved medicines, or undergoing different phases 
of human clinical trials [58–60, 107]. By 2016, already 51 
FDA-approved nanotherapies were available while 77 
nanoproducts were in clinical trials [107]. Majority of 
these nanoproducts contained drugs previously approved 
by the FDA. In principle many of the nanodrugs are 
designed as encapsulations of FDA approved drugs in 
biodegradable and biocompatible NPs such as liposomes, 
micelles or polymeric NPs [58–60, 107]. Inorganic or 
metallic nanomaterials such as AuNPs, iron oxide, silica 
etc., are still in phase I–III clinical trials [59, 107, 108]. 
The lack of information on the fate of metallic NPs 
in vivo, could be the reason why there is a delay in their 
translation and transition into clinical medication. Metal-
lic NPs are non-biodegradable in nature; their ability to 
pass through cellular components raises health concerns.
Various nanocarriers used in clinical practice serve 
as drug delivery agents to ascertain distribution of 
drugs/treatment to desired targets [108]. Most of the 
Fig. 8 Photothermal lipolysis of adipocytes in the subcutaneous WAT. The AHP-targeted hyaluronate-hollow AuNSs localized in the adipocytes 
after noninvasive transdermal delivery, and induced photothermal lipolysis in vivo. Reproduced with permission [18]. Copyright 2017, American 
Chemical Society. HA-HAuNS-ATP AHP-targeted hyaluronate-hollow AuNS, NIR near infrared
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nanoformulations in clinical trials are untargeted and 
rely on the EPR effect to target and accumulate in the 
diseased tissues [108]. In contrast, targeted therapies 
use ligands that bind to disease associated biomarkers 
and accumulate specifically in cells that express the tar-
get receptor. Both the passive and active-targeted nano-
systems demonstrated reduced bystander effects and 
enhanced the drug’s therapeutic index in pre-clinical and 
clinical studies [58–60].
Nanomedicines have been on the market since 1990 
for treatment of various diseases including cancer, severe 
combined immunodeficiency disease, and arthritis [59, 
60, 107]. Most of the nanoformulations are comprised 
of drugs currently used clinically for disease treatment. 
The drugs are encapsulated within the nanomaterials to 
improve their pharmacokinetic properties [107]. Some of 
the nanodrugs already on the market are listed in Table 2. 
The earliest application of nanomedicine was in cancer 
treatment, where liposomes were used to deliver chemo-
therapeutic payloads to the tumor site [109]. Doxil and 
Abraxane are the first FDA-approved chemotherapeutic 
nanodrugs in 1995 and 2005, respectively. Abraxane, an 
albumin-bound paclitaxel NP formulation, was approved 
for treatment of metastatic breast cancer in the United 
States of America (USA) and showed greater efficacy 
with an improved safety profile than free paclitaxel [110, 
111]. Doxorubicin is one of the drugs used for treatment 
of cancer and is associated with cardiac toxic side effects. 
The biodegradable liposomes used to deliver Doxoru-
bicin to the tumor, retains the drug efficacy and increase 
circulation time compared to the free drug. Doxil is 
FDA-approved for treatment of refractory ovarian can-
cer, breast cancer and Kaposi’s sarcoma [111, 112]. The 
number of diseases treated by Doxil has since increased, 
covering a wider range of diseases including multiple 
sclerosis, neutropenia, anemia (refer to Table  2). The 
nanosystems had reduced systemic toxicity and enhanced 
tumor specificity. Some of the nanodrugs rely on the EPR 
effect to target diseased cells/tissues, especially in can-
cer [107]. In a pathological state, EPR is characterized by 
pathological and excessive angiogenesis and increased 
secretion of various permeability mediators that provide 
an opportunity for more selective targeting of NPs as it 
does not occur in normal tissues or organs [6, 54, 55]. 
These effects can be further enhanced by targeting dis-
ease-specific markers, active targeting can be achieved by 
using antibodies peptides, aptamers or ligands that binds 
to these disease biomarkers with high affinity [11].
Potential clinical applications of nanodrugs in obesity
There are currently no nano-based drugs that are either 
clinically approved or in clinical trials for the treatment of 
obesity. However, based on published literature reviewed 
here and the potential of the nanodrugs, it is just a mat-
ter of time before these nanodrugs will be tested in clini-
cal trials and made available to the market. The studies 
reviewed here provide definitive proof of the concept that 
nanomedicine can be a feasible strategy for the treatment 
of obesity, by improving patient’s compliance and possi-
bly eradicate most of the challenges associated with the 
commercially available anti-obesity drugs [12–15]. The 
nanodrugs listed in Table 2 have been used successfully 
in treatment of chronic diseases, especially cancer. Since 
cancer and obesity share some similar characteristics 
(e.g. high proliferation rate, compromised vascular sys-
tem angiogenesis) [6, 37, 54, 55], nanomedicine can work 
quite as good in obesity. So far, since obesity has benefit-
ted from similar treatment strategies as cancer, it might 
also benefit from nano-based anti-angiogenic, anti-neo-
plastic [37] and transdermal therapies in future [18, 19].
The reviewed strategies prove that it is possible to 
reduce body weight by targeting the WAT vasculature 
using nano-based anti-angiogenic inhibitors [13, 14], 
WAT browning agents [12, 16], and photothermal agents 
[18, 19]. The three strategies were effective, not only for 
reversal of obesity at lower doses, but also for reduc-
tion of bystander effects and normalization of metabolic 
activities. More importantly, these nanosystems delivered 
non-specific and poorly soluble drugs to the target and 
confined their effects directly on the diseased cells while 
sparing surrounding tissues [12, 74]. Non-invasive and 
painless microneedle patches also presented a promising 
platform for transcutaneous anti-obesity drug delivery 
systems [16].
The ability of nanocarriers to increase the bioavailabil-
ity of drugs was demonstrated by using some drugs with 
anti-obesity effects, current and those that were with-
drawn. Encapsulating cannabinoids in NPs increased 
transportation across the hydrophobic mucosa, reduced 
adverse effects [113], enhanced drug absorption in the 
intestinal tissues and drug biodistribution in rat brains 
[114]. Nano-based delivery systems further improved the 
stability and activity of orlistat, where the nanoemulsi-
fied orlistat showed enhanced dissolution rate and lipase 
inhibition action when compared to the free drug [115]. 
Similar effects were observed when orlistat was embed-
ded in nanoemulsified multi-unit pellet system [116], 
and polymer nanocarriers [117]. These systems were 
able to mask the drug’s hydrophobicity, reduced orlistat 
induced side effects and increase its bioavailability [115–
117]. The efficacy and bioavailability of rimonabant, an 
anti-obesity drug withdrawn due to lethal effects, was 
improved by encapsulating the drug in nanostructured 
lipid carriers [118] and amorphous mesoporous magne-
sium carbonate [119]. Although the therapeutic effects of 
orlistat and rimonabant nano-drugs is yet to be evaluated 
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in vivo [118], the nano-based formulations represent an 
important tool for improvement of existing and with-
drawn drugs. Anti-obesity drugs such as rimonabant and 
sibutramine can thus be repurposed using the nanotech-
nology-based delivery systems to reduce toxic effects and 
increase drug efficacy.
Conclusions
Obesity is a global health threat and requires urgent 
attention to reverse the disease and prevent its progres-
sion to other chronic diseases [4, 5]. The conventional 
therapies, which are only successful for a limited period, 
brings with them undesirable bystander toxic effects [5]. 
Nanotechnology-based strategies have shown poten-
tial in improving drug delivery, drug uptake [15, 63] and 
therapeutic index of potential anti-obesity agents in pre-
clinical studies [13, 14, 62]. Furthermore, nanotechnol-
ogy also improved the pharmacokinetics of anti-obesity 
drugs (current and withdrawn) [115–119]. The FDA-
approved nanodrugs showed promising clinical health 
benefits in cancer treatment for over 20  years [58, 59], 
and based on Sect. 4.2, they could significantly improve 
the safety and efficacy of the anti-obesity drugs [114–
120]. Nano-based delivery systems offer great opportu-
nities to rescue anti-obesity drugs that were withdrawn 
from the market [114–120], by enhancing their sensitiv-
ity and selectivity through targeting of disease-associated 
biomarkers [13–15]. These nanosystems can be useful in 
addressing drawbacks associated with anti-obesity drugs, 
especially non-specificity, use of large doses, and poor 
drug solubility [114–120]. The reviewed preclinical stud-
ies proved that targeted nanotherapy can be delivered 
to diseased WATs and minimized off-target toxic effects 
[13, 14]. Targeting the WATs and its vasculature through 
nano-based systems could be an ideal target in develop-
ing therapeutic strategies with sustainable anti-obesity 
effects.
Orally administered drugs such as orlistat suffer from 
poor solubility [31, 32], therefore drug specificity and 
efficiency can be improved by using nano-based systems. 
The delivery systems can be tailored based on the drug’s 
properties, and exploiting the NP’s physico-chemical 
properties. Concern about metal NP toxicity can also be 
addressed by using biodegradable nanocarriers such as 
liposomes and polymers which are already used clinically 
due to their biocompatibility [59, 60]. These systems, 
especially liposomes have been used for > 20 years as drug 
delivery systems [120]. Drug release is easily controlled, 
thereby increasing drug specificity by creating systems 
that are responsive to the disease environment, such as 
pH and temperature. This review highlights the nano-
based strategies for the improvement in the reversal of 
obesity and obesity-induced diseases, and can help curb 
the epidemic in its fracks and reduce obesity-associated 
chronic diseases.
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